Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan + rosuvastatin
- Development stage
- Phase 1
- Lead developer
- Alvogen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**candesartan + rosuvastatin** is a fixed-dose oral combination drug used for the concurrent treatment of hypertension (high blood pressure) and hypercholesterolemia (high cholesterol). Candesartan is a selective angiotensin II type 1 receptor antagonist that blocks the action of angiotensin II, thereby reducing blood vessel constriction and lowering blood pressure. Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) which lowers cholesterol by inhibiting the enzyme involved in cholesterol biosynthesis, reducing LDL cholesterol and total cholesterol levels. The combination improves medication adherence and provides synergistic cardiovascular protection by addressing two major risk factors for cardiovascular disease: elevated blood pressure and dyslipidemia[1][2][6].
- Other names
- candesartan + rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on candesartan + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan + rosuvastatin.